

L a b o r a t o r y *News*

VOL. 39, NO. 6 - SEPTEMBER 1, 2016

Inside This Issue

HER2 REFLEX CHANGE 1

**HER2 SPECIMEN REQUIREMENTS:
RECORDING UPDATE AND
TISSUE HANDLING REMINDER**
..... 2

HER2 REFLEX CHANGE

*Yeping Sun, MD, Anatomic Pathology;
Gene R. Shaw, MD, Clinical Pathology;
Laura Bliven, BS, HT(ASCP), QIHC, Histology Lab*

Effective September 1, 2016, Marshfield Labs will modify the HER2 testing algorithm for breast and gastroesophageal cancers (test codes: **HER2NEU, ERA/PRA, FHER2**). In addition to cases interpreted as 2+ by immunohistochemistry (IHC), those read as 1+ will also reflex to fluorescence in-situ hybridization (FISH). This change will help ensure that patients eligible for HER2 directed therapies are more consistently identified.

Marshfield Labs switched from a polyclonal to a monoclonal antibody for HER2 IHC in January, 2016. Although this provided greater specificity, it also resulted in more 1+ cases of which about 10% are amplified by FISH (usually low-level amplification) using the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines. Using our current algorithm, these cases would have been considered negative and would not have undergone further testing.

Until now, Marshfield Labs has used the most common algorithm starting with IHC (read on a scale of 0 to 3+), [with 0/1+ negative, 2+ equivocal and 3+ positive] and reflexing only 2+ cases to FISH. Cases interpreted as 3+ (regardless of FISH results) or FISH positive are treatment-eligible. IHC is less resource intensive than FISH, making it an attractive first tier test if a significant number of cases can forgo FISH testing. With the proposed 1+/2+ algorithm, it is estimated that about half of cases will be reflexed to FISH. Cases interpreted as 0 or 3+ by IHC will not be reflexed.

Trastuzumab (Herceptin), along with other more recently



developed therapies directed at HER2-positive cancers, have significantly improved outcomes for these patients, who historically have had an unfavorable prognosis. Thus, Marshfield Clinic oncologists feel that the sensitive detection of these patients is paramount. This testing change will apply to both Marshfield Clinic patients and those from Outreach clients.

QUESTIONS

- Gene Shaw, MD, Clinical Pathology
- Phone number: 800-222-5835. 

HER2 SPECIMEN REQUIREMENTS: RECORDING UPDATE AND TISSUE HANDLING REMINDER

Faith Bosmans, Pathologists' Assistant, Pathology Lab

RECORDING UPDATE

In 2013, to improve testing accuracy and reduce the risks associated with false positive and false negative results, ASCO/CAP collaborated in developing specimen handling and fixation guidelines for HER2, Estrogen Receptor (ERA), and Progesterone Receptor (PRA) testing. These guidelines currently target breast tissues *only*, not gastrointestinal tissues. The Histology Test Request / Requisition forms, the web portal, and the Clinical Order Manager (COM) system (Fig. 1, page 3) are being updated to ensure the following information is recorded:

- 1. Specimen removal time and time placed in fixative** (This will allow calculation of the *cold ischemic time*, i.e., the amount of time between removal from the body and placement in fixative.) This time should be less than one hour.
- 2. Fixative type** – should be 10% neutral buffered formalin (NBF).
- 3. Fixative duration** – should be more than 6 hours but less than 72 hours.
If histology staff process the tissue, they will calculate fixative duration.

Previous test request/requisition forms should be discarded and new forms ordered:

- Marshfield Clinic departments should order "Histology Test Request" form #9-25025, by emailing a project request form to creative.services@marshfieldclinic.org or using the new online ordering system, *myPrint Services*.
- External clients should use their site's process for ordering "Histology Requisition" forms.

SPECIMEN HANDLING

Breast specimens must be inked and cut into before being placed in formalin!

- 1. BEFORE** breast is cut into, it needs to be inked so the true margin is not compromised.
Marshfield Labs inks as follows:
 - Superior - Blue
 - Inferior - Green
 - Medial - Red
 - Lateral - Orange
 - Anterior - Yellow
 - Posterior - Black
- 2. Breast** specimens need to be CUT INTO so that the formalin fixative can come in direct

continued on page 3

contact with the tumor. Since formalin only penetrates tissue at a rate of 1 mm/hr., it may not fix the tumor for hours or even days, resulting in autolysis and potentially inaccurate hormone testing results. Suggested cuts are: 1-2 cuts for smaller lumpectomy specimens, 2-3 cuts for larger lumpectomy specimens, 3-4 cuts for a mastectomy specimen.

3. The breast tissue must be placed into formalin ASAP, but no later than one hour after being removed from the patient. The time removed and time placed in formalin must be indicated.


QUESTIONS

- Faith Bosmans, *Pathologists' Assistant, PA, Pathology Lab*
- Phone number: 800-222-5835 or E-mail: bosmans.faith@marshfieldclinic.org 

FIG. 1: CLINICAL ORDER MANAGER (COM) CHANGES

Two new questions will be added after 'Procedure Requested':

- FOR BREAST ONLY - For Each Breast Specimen Enter Removal Time
**Note: Removal time and time to fixative should be less than one hour.
- FOR BREAST ONLY - For Each Breast Specimen Enter Time in Fixative



Related Questions

Histology

** Note: The order ticket MUST be sent to the Lab with the histology specimen! **

Procedure Requested: Tissue Microscopic Exam

FOR BREAST ONLY - For Each Breast Specimen Enter Removal Time:

**Note: Removal time and time to fixative should be less than one hour.

FOR BREAST ONLY - For each Breast Specimen Enter Time in Fixative:

History:

Differential Diagnosis:

Procedure:

Location: Clinic Department

Call Back Number for INTRAOPERATIVE Results:

* = Required

OK Cancel Help